E Fund Management Co. Ltd. Sells 5,949 Shares of Geron Co. (NASDAQ:GERN)

E Fund Management Co. Ltd. decreased its stake in shares of Geron Co. (NASDAQ:GERN) by 6.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 85,539 shares of the biopharmaceutical company’s stock after selling 5,949 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Geron were worth $303,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new position in shares of Geron during the 4th quarter worth about $28,000. Readystate Asset Management LP bought a new position in shares of Geron during the 3rd quarter worth about $58,000. Rovin Capital UT ADV bought a new position in shares of Geron during the 3rd quarter worth about $62,000. Empowered Funds LLC bought a new position in shares of Geron during the 3rd quarter worth about $67,000. Finally, Monterey Private Wealth Inc. bought a new position in shares of Geron during the 4th quarter worth about $63,000. Institutional investors own 73.71% of the company’s stock.

Geron Price Performance

NASDAQ:GERN opened at $1.73 on Friday. The firm has a market cap of $1.10 billion, a PE ratio of -5.41 and a beta of 0.53. Geron Co. has a 12 month low of $1.46 and a 12 month high of $5.34. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The company’s 50-day moving average price is $2.77 and its two-hundred day moving average price is $3.67.

Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million. On average, equities analysts anticipate that Geron Co. will post -0.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. B. Riley lowered shares of Geron from a “buy” rating to a “neutral” rating and decreased their target price for the company from $3.50 to $2.00 in a research report on Thursday, February 27th. Needham & Company LLC decreased their target price on shares of Geron from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Stifel Nicolaus decreased their target price on shares of Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. HC Wainwright lowered shares of Geron from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 26th. Finally, Barclays reiterated an “overweight” rating and set a $4.00 target price (down from $9.00) on shares of Geron in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Geron currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.68.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.